Study design
SUSTAIN-3, an ongoing phase 3, open-label, multicenter (SUSTAIN-3 has a 4-week induction phase (if applicable) and an optimization/maintenance phase of variable duration. Participants in 1 of 6 phase 3, “parent” studies of esketamine and for whom benefit versus risk was favorable were enrolled into either the 4-week induction phase or the long-term optimization/maintenance phase of SUSTAIN-3 based on their status at the end of the parent study (Fig. SUSTAIN-3 (clinical trials.gov identifier: NCT02782104) and the parent studies (identifiers: NCT02417064, NCT02418585, NCT02422186, NCT02493868, NCT02497287, NCT03434041) are registered at clinicaltrials.gov.